Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET

Company Participants

Elizabeth Higgins - Investor Relations

Jill Milne - Co Founder, CEO, President & Director

Noah Clauser - CFO & Treasurer

Christopher Morabito - Chief Medical Officer

Andrea Matthews - Chief Business Officer

Andrew Komjathy - Chief Commercial Officer

Conference Call Participants

Eun Yang - Jefferies

Sam Slutsky - LifeSci Capital

Hartaj Singh - Oppenheimer

Farhana Sakloth - Ladenburg

Joe Pantginis - H.C. Wainwright

Operator

Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode. [Operator Instructions]

As a reminder, this call is being recorded and a replay will be made available on the Astria website following the conclusion of the event. I'd now like to turn the call over to Liz Higgins, Director of Communications and Investor Relations at Astria Therapeutics. Please go ahead, Liz.

Elizabeth Higgins

Thank you, Tara. Welcome to today's Astria Therapeutics Q3 2023 conference call. With me today are Jill Milne, Chief Executive Officer, Christopher Morabito, Chief Medical Officer; Andrew Komjathy, Chief Commercial Officer; Andrea Matthews, Chief Business Officer and Noah Clauser, Chief Financial Officer. We issued a press release this morning summarizing our corporate update and third quarter financial results, which we will reference on today's call and is available on our website. We are also using slides during today's call that are available within the events and presentation section in the investors part of our website.

I would like to note during today's event, as mentioned on slide 2, we will be making forward-looking statements related to our business based on current and future expectations. Actual results may differ materially from those indicated by these statements as a result of a variety of risks and uncertainties, including those discussed in our most recent Form 10-K and our subsequent SEC filings. Such statements may represent our judgment as of today and we undertake no obligation to publicly update any forward-looking statements except as required by law.

I will now pass the call over to Jill Milne, Chief Executive Officer. Jill?

Jill Milne

Good morning and thank you for joining our earnings call. We've had an exciting few months at Astria and are in a strong position to close out the year. Just a few days ago at ACAAI annual meeting, we shared positive Phase 1a data for STAR-0215 of our lead program that supports our vision for STAR-0215 to be the first choice preventative treatment for Hereditary Angioedema or HAE. The data confirm the potential for STAR-0215 to prevent HAE attacks with dosing two or four times per year. We aim to provide patients the option to choose a dosing regimen that works best for their lives, which we will review more on the coming slides.